MRSN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRSN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Mersana Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.
For the Biotechnology subindustry, Mersana Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:
* The bar in red indicates where Mersana Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.
Mersana Therapeutics (NAS:MRSN) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation
EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of Mersana Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.
Anna Protopapas | director, officer: President and CEO | MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Mohan Bala | officer: SVP, Chief Development Officer | C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Tushar Misra | officer: Chief Manufacturing Officer | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Brian Deschuytner | officer: Sr. VP, Finance & Product stgy | 840 MEMORIAL DRIVE, CAMBRIDGE MA 01776 |
Ashish Mandelia | officer: VP, Controller | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Timothy B Lowinger | officer: Chief Scientific Officer | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Alejandra Carvajal | officer: Chief Legal Officer | C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Arvin Yang | officer: Chief Medical Officer | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Michael J. Kaufman | officer: Sr VP Chmistry, Man & Control | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Allene M. Diaz | director | C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Eva M. Jack | officer: CBO, Treasurer & Secretary | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Lawrence M Alleva | director | 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Scott D Sandell | 10 percent owner |
From GuruFocus
By PRNewswire • 06-27-2023
By PRNewswire • 06-23-2023
By PRNewswire • 08-10-2023
By PRNewswire • 06-27-2023
By PRNewswire • 06-28-2023
By GuruFocus Research • 11-07-2023
By Marketwired • 07-06-2023
By PRNewswire • 07-17-2023
By Marketwired • 10-31-2023
By Marketwired • 10-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.